Dongrong Yu

Dongrong Yu

Auto-generated profile, based on publicly available information

Dongrong Yu

Department of Nephrology, Hangzhou TCM Hospital of Zhejiang Chinese Medical University (Hangzhou Hospital of Traditional Chinese Medicine), Hangzhou 310007, Zhejiang, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2022 in Analytical Cellular Pathology
Verified
Journal Article
Open access
PDF file
LMLichan Mao
Lichan Mao
YDYin Ding
Yin Ding
DYDongrong Yu
Dongrong Yu
JYjiazhen yin
jiazhen yin
JYJin Yu
Jin Yu
Tetrandrine (Tet), a compound found in a traditional Chinese medicine, presents the protective effect for kidney function. Our study is aimed at clarifying the efficacy and underlying mechanism of Tet on podocyte injury. In this study, podocyte injury was induced in rats with adriamycin (ADR), and MPC5 podocytes were constructed with TRPC6 overexpression. We found that Tet treatment reduced the levels of proteinuria, serum creatinine, and blood urea nitrogen and increased plasma albumin levels in ADR-induced rats. Tet reduced intracellular Ca2+ influx and apoptosis in MPC5 podocytes overexpressing TRPC6. Tet downregulated the expression of renal TRPC6, RhoA, and ROCK1 and upregulated the expression of synaptopodin; meanwhile, it reduced calcineurin activity in vivo and in vitro. In conclusion, Tet protects against podocyte by affecting TRPC6 and its downstream RhoA/ROCK1 signaling pathway.

8 June 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
JYjiazhen yin
jiazhen yin
DYDongrong Yu
Dongrong Yu
LMLichan Mao
Lichan Mao
CZCaifeng Zhu
Caifeng Zhu
JYJin Yu
Jin Yu
Background. Fangji Huangqi decoction (FHD) is a traditional Chinese medicine formula that has the potential efficacy for nephrotic syndrome (NS) treatment. This study aims to explore the effects and underlying mechanisms of FHD against NS via network pharmacology and in vivo experiments. Methods. The bioactive compounds and targets of FHD were retrieved from the TCMSP database. NS-related targets were collected from GeneCards and DisGeNET databases. The compound-target and protein-protein interaction networks were constructed by Cytoscape 3.8 and BisoGenet, respectively. GO and KEGG analyses were performed by the DAVID online tool. The interactions between active compounds and hub genes were revealed by molecular docking. An NS rat model was established to validate the renoprotective effects and molecular mechanisms of FHD against NS in vivo. Results. A total of 32 hub genes were predicted to play essential roles in FHD treating NS. Eight main bioactive compounds of FHD had the good affinity with 9 hub targets (CCL2, IL-10, PTGS2, TNF, MAPK1, IL-6, CXCL8, TP53, and VEGFA). The therapeutic effect of FHD on NS was closely involved in the regulation of inflammation and PI3K-Akt pathway. In vivo experiments confirmed the renoprotective effect of FHD on NS, evidenced by reducing the levels of proteinuria, serum creatinine, blood urea nitrogen, and inflammatory factors in NS rats. The PI3K activator 740Y-P weakened the effects of FHD against NS. Furthermore, FHD downregulated the levels of PTGS2, MAPK1, IL-6, and p-Akt in NS rats. Conclusions. FHD alleviates kidney injury and inflammation in NS by targeting PTGS2, MAPK1, IL-6, and PI3K-Akt pathway.

1 February 2024 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
YCYinfeng Chen
Yinfeng Chen
XWXiaying Wang
Xiaying Wang
JMJie Min
Jie Min
JZJie Zheng
Jie Zheng
XTXuanli Tang
Xuanli Tang
DJDe Jin
De Jin
Purpose: This study investigated the mechanism of TSF in treating DN through network pharmacology, molecular docking, and experimental validation. Methods: To identify critical active ingredients, targets, and DN genes in TSF, multiple databases were utilized for screening purposes. The drug-compound-target network was constructed using Cytoscape 3.9.1 software for network topological analysis. The protein interaction relationship was analyzed using the String database platform. Metascape database conducted enrichment analysis on the key targets using Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes. The renoprotective effect was evaluated using a mouse model of diabetic nephropathy (db/db mice) that occurred spontaneously. Validation of the associated targets and pathways was performed using Western Blot (WB), Polymerase Chain Reaction (PCR), and Immunohistochemical methods (IHC). Results: The network analysis showed that the TSF pathway network targeted 24 important targets and 149 significant pathways. TSF might have an impact by focusing on essential objectives such as TP53, PTEN, AKT1, BCL2, BCL2L1, PINK-1, PARKIN, LC3B, and NFE2L2, along with various growth-inducing routes. Our findings demonstrated that TSF effectively repaired the structure of mitochondria in db/db mice. TSF greatly enhanced the mRNA levels of PINK-1. WB and IHC findings indicated that TSF had a notable impact on activating the PINK-1/PARKIN signaling pathway in db/db mice, significantly increasing LC3 and NRF2 expression. Conclusion: Our results indicate that TSF effectively addresses DN by activating the PINK-1/PARKIN signaling pathway and enhancing Mitochondrion structure in experimental diabetic nephropathy.

7 October 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
DJDe Jin
De Jin
XTXiao Tu
Xiao Tu
WXWanyue Xu
Wanyue Xu
HZHonghui Zheng
Honghui Zheng
JZJiali Zeng
Jiali Zeng
FWFeng Wan
Feng Wan

1 July 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
JCJia-Wei Cao
Jia-Wei Cao
YTYue-Wen Tang
Yue-Wen Tang
MJMeng-Ya Jiang
Meng-Ya Jiang
MLMeng-Dan Lu
Meng-Dan Lu
RYRuchun Yang
Ruchun Yang
FWFeng Wan
Feng Wan
Background: IgA nephropathy (IgAN) is a significant contributor to kidney failure and death, with limited therapeutic options. Gui-qi-yi-shen (GQYS) granules are a classic Chinese medicine prescription for treating IgAN. Nevertheless, the underlying molecular mechanism is still unclear. Purpose: To elucidate the mechanism by which GQYS exerts its therapeutic effects in IgAN treatment. Materials and Methods: Itgam-IRES-hCD89 mice (eight-week-old) were divided into four groups: IgAN, low-dose GQYS (GQYS-L, 5.2 g/kg), high-dose GQYS (GQYS-H, 10.4 g/kg), and Losartan (6.5 mg/kg). Coincident C57/BL6 mice were used as controls. Periodic acid-Schiff (PAS) staining, biochemical analyses, and immunofluorescence (IF) were used for therapeutic evaluation. Network pharmacology and transcriptomic analyses were performed to investigate the potential mechanisms of GQYS, while Western blotting and IF were performed to confirm these actions. Results: Compared to the model group, 24 h proteinuria and alanine aminotransferase levels were significantly reduced in the GQYS groups. PAS staining showed that IgAN mice exhibited glomerular mesangial hypercellularity as well as matrix expansion, whereas these pathologies were alleviated in the GQYS groups. IF results revealed that GQYS reduced deposition of IgA and C3 in the glomerular mesangial areas compared to that in the model mice. Network pharmacology and transcriptomic analyses identified genes and pathways that may be associated with the effects of GQYS against IgAN. Western blotting and IF results indicated GQYS attenuated the expression of TLR4/MyD88/NF-kB and IL-6/JAK2/STAT3 signaling pathway related proteins. Conclusion: GQYS reduced proteinuria and ameliorate renal pathological damage in IgAN via TLR4/MyD88/NF-kB and IL-6/JAK2/STAT3 signaling, offering a promising therapeutic strategy.

7 March 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
CYCan Yu
Can Yu
WSWen Shi
Wen Shi
ECEnhui Chen
Enhui Chen
YQYang Qiu
Yang Qiu
LGLi Gao
Li Gao
DJDe Jin
De Jin
Background: In diabetic patients, non-diabetic kidney disease (NDKD) may occur independently or alongside diabetic kidney disease (DKD). This study explored the utility of kidney biopsy in type 2 diabetes mellitus (T2DM) patients and the predictability of diagnosing DKD combined with NDKD using clinical and laboratory data.Methods: This retrospective study examines medical records of T2DM patients who underwent percutaneous renal biopsy at Hangzhou TCM Hospital, Zhejiang Chinese Medical University, from 2012 to 2023. The patient’s demographic, clinical, blood test and pathological examination data were retrieved from their medical records. Multivariate regression analysis evaluated predictive factors for NDKD superimposed on DKD (DKD+NDKD).Results: A total of 285 patients were analyzed. The average age at the time of renal biopsy was 53.26 ± 10.55 years. The duration of diabetes was 93.19 ± 70.78 months. Of the patient population, 35.44% (101/285) were diagnosed with DKD alone, while 64.56% (184/285) had DKD+NDKD. Immunoglobulin A nephropathy was the most common pathological type in the DKD+NDKD group, accounting for 37.30% of the patients. Cystatin C [HR=2.688, 95% CI 1.035-6.879, P < 0.05] independently predicted the prognosis of patients with DKD+NDKD.Conclusions: These findings suggest that cystatin C plays a role in influencing the prognosis of patients with DKD + NDKD, indicating that NDKD patients might require distinct treatment strategies compared to those with DKD alone. However, further prospective clinical trials are needed to provide more clarity on the prognosis and outcomes of diabetic patients.